NT5E and neoplasm: Tumour CD39/CD73 hydrolyse ATP to micromolar adenosine that suppresses NK and microglia via A2A/A2B; the A2A antagonist ciforadenant (K i 5 nM) and anti-CD73 mAb oleclumab now advance in phase II GBM trials.